CN1753686A - 用于促进从中枢神经系统损伤中恢复的方法、组合物和试剂盒 - Google Patents

用于促进从中枢神经系统损伤中恢复的方法、组合物和试剂盒 Download PDF

Info

Publication number
CN1753686A
CN1753686A CNA008145091A CN00814509A CN1753686A CN 1753686 A CN1753686 A CN 1753686A CN A008145091 A CNA008145091 A CN A008145091A CN 00814509 A CN00814509 A CN 00814509A CN 1753686 A CN1753686 A CN 1753686A
Authority
CN
China
Prior art keywords
cell
polypeptide
dexedrine
growth factor
stem cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA008145091A
Other languages
English (en)
Chinese (zh)
Inventor
S·P·芬克莱斯坦
E·Y·斯尼德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Childrens Medical Center Corp
Original Assignee
General Hospital Corp
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Childrens Medical Center Corp filed Critical General Hospital Corp
Publication of CN1753686A publication Critical patent/CN1753686A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA008145091A 1999-08-18 2000-08-18 用于促进从中枢神经系统损伤中恢复的方法、组合物和试剂盒 Pending CN1753686A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14956199P 1999-08-18 1999-08-18
PCT/US2000/022843 WO2001012236A2 (en) 1999-08-18 2000-08-18 Methods, compositions and kits for promoting recovery from damage to the central nervous system

Publications (1)

Publication Number Publication Date
CN1753686A true CN1753686A (zh) 2006-03-29

Family

ID=22530841

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA008145091A Pending CN1753686A (zh) 1999-08-18 2000-08-18 用于促进从中枢神经系统损伤中恢复的方法、组合物和试剂盒

Country Status (10)

Country Link
EP (1) EP1210106A2 (ja)
JP (1) JP2003507349A (ja)
CN (1) CN1753686A (ja)
AU (1) AU6790300A (ja)
BR (1) BR0013388A (ja)
CA (1) CA2380953A1 (ja)
IL (1) IL148175A0 (ja)
MX (1) MXPA02001719A (ja)
NO (1) NO20020779L (ja)
WO (1) WO2001012236A2 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103230581A (zh) * 2011-11-10 2013-08-07 陈锦辉 用于治疗创伤性脑损伤的组合物和方法
CN103421800A (zh) * 2013-09-05 2013-12-04 新乡医学院 用于治疗脊髓损伤的重组基因、重组载体和重组细胞
CN103555747A (zh) * 2013-10-22 2014-02-05 深圳先进技术研究院 胶质细胞bFGF表达提高系统及其构建方法和应用
CN101600966B (zh) * 2006-06-02 2014-07-02 辉瑞产品公司 循环肿瘤细胞分析
CN107148278A (zh) * 2014-08-15 2017-09-08 财团法人卫生研究院 利用神经干细胞与IL12p40增强神经再生的方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021668D0 (en) * 2000-09-04 2000-10-18 Smithkline Beecham Plc New use
DE10111486A1 (de) * 2001-03-09 2002-10-02 Ralph R Dawirs Verwendung einer oder mehrerer neuroaktiver Substanzen zur Behandlung der Parkinsonschen Krankheit
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US7635467B2 (en) 2002-01-14 2009-12-22 The Board Of Trustees Of The University Of Illinois Mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
US7432243B2 (en) * 2002-04-08 2008-10-07 The Scripps Research Institute Truncated 24kDa basic fibroblast growth factor
US8118722B2 (en) 2003-03-07 2012-02-21 Neuronetics, Inc. Reducing discomfort caused by electrical stimulation
US7153256B2 (en) 2003-03-07 2006-12-26 Neuronetics, Inc. Reducing discomfort caused by electrical stimulation
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8093205B2 (en) 2003-12-01 2012-01-10 Medtronic, Inc. Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis
US7651459B2 (en) 2004-01-06 2010-01-26 Neuronetics, Inc. Method and apparatus for coil positioning for TMS studies
US8177702B2 (en) 2004-04-15 2012-05-15 Neuronetics, Inc. Method and apparatus for determining the proximity of a TMS coil to a subject's head
US7601115B2 (en) 2004-05-24 2009-10-13 Neuronetics, Inc. Seizure therapy method and apparatus
WO2006023530A2 (en) * 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
US7857746B2 (en) 2004-10-29 2010-12-28 Nueronetics, Inc. System and method to reduce discomfort using nerve stimulation
US8088058B2 (en) 2005-01-20 2012-01-03 Neuronetics, Inc. Articulating arm
US7396326B2 (en) 2005-05-17 2008-07-08 Neuronetics, Inc. Ferrofluidic cooling and acoustical noise reduction in magnetic stimulators
US7824324B2 (en) 2005-07-27 2010-11-02 Neuronetics, Inc. Magnetic core for medical procedures
US20070135859A1 (en) * 2005-12-09 2007-06-14 Peter Eriksson Use of transcranial magnetic stimulation to improve memory and stress related syndromes in humans
DE102007003565B4 (de) 2007-01-24 2012-05-24 Forschungszentrum Jülich GmbH Vorrichtung zur Reduktion der Synchronisation neuronaler Hirnaktivität sowie dafür geeignete Spule
US9884200B2 (en) 2008-03-10 2018-02-06 Neuronetics, Inc. Apparatus for coil positioning for TMS studies
CA2736018C (en) 2008-09-16 2015-11-03 Stephanie Merchant Compositions for treating or delaying the onset of hair loss
EP2701727B1 (en) * 2011-03-04 2019-05-08 The Regents of The University of California Locally released growth factors to mediate motor recovery after stroke

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612211A (en) * 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
AU4995193A (en) * 1992-08-04 1994-03-03 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
JP2002503942A (ja) * 1994-03-07 2002-02-05 イミュネックス・コーポレーション 体外での細胞培養及び移植用キット
KR20000064752A (ko) * 1996-03-22 2000-11-06 더 제네랄 호스피탈 코포레이션 중추신경계허혈또는외상의발현후폴리펩티드성장인자를투여하는방법
US20020136705A1 (en) * 1998-06-30 2002-09-26 Jonathan Dinsmore Porcine spinal cord cells and their use in spinal cord repair
AU780994B2 (en) * 1999-05-14 2005-04-28 Henry Ford Health System Bone marrow transplantation for treatment of stroke

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101600966B (zh) * 2006-06-02 2014-07-02 辉瑞产品公司 循环肿瘤细胞分析
US8940493B2 (en) 2006-06-02 2015-01-27 Veridex Llc Circulating tumor cell assay
CN103230581A (zh) * 2011-11-10 2013-08-07 陈锦辉 用于治疗创伤性脑损伤的组合物和方法
CN103230581B (zh) * 2011-11-10 2016-12-21 陈锦辉 用于治疗创伤性脑损伤的组合物和方法
CN103421800A (zh) * 2013-09-05 2013-12-04 新乡医学院 用于治疗脊髓损伤的重组基因、重组载体和重组细胞
CN103421800B (zh) * 2013-09-05 2015-07-22 新乡医学院 用于治疗脊髓损伤的重组基因、重组载体和重组细胞
CN103555747A (zh) * 2013-10-22 2014-02-05 深圳先进技术研究院 胶质细胞bFGF表达提高系统及其构建方法和应用
CN103555747B (zh) * 2013-10-22 2015-04-08 深圳先进技术研究院 胶质细胞bFGF表达提高系统及其构建方法和应用
CN107148278A (zh) * 2014-08-15 2017-09-08 财团法人卫生研究院 利用神经干细胞与IL12p40增强神经再生的方法
CN107148278B (zh) * 2014-08-15 2021-06-29 财团法人卫生研究院 利用神经干细胞与IL12p40增强神经再生的方法

Also Published As

Publication number Publication date
WO2001012236A2 (en) 2001-02-22
MXPA02001719A (es) 2003-09-25
BR0013388A (pt) 2002-08-27
IL148175A0 (en) 2002-09-12
NO20020779D0 (no) 2002-02-15
EP1210106A2 (en) 2002-06-05
WO2001012236A3 (en) 2001-08-30
NO20020779L (no) 2002-04-15
WO2001012236A9 (en) 2002-09-06
CA2380953A1 (en) 2001-02-22
JP2003507349A (ja) 2003-02-25
AU6790300A (en) 2001-03-13

Similar Documents

Publication Publication Date Title
CN1753686A (zh) 用于促进从中枢神经系统损伤中恢复的方法、组合物和试剂盒
US10787641B2 (en) Therapeutic use of CD31 expressing cells
CN1127343C (zh) 治疗哺乳动物疾病的成肌细胞组合物
ES2910032T3 (es) Métodos de diferenciación in vitro de neuronas dopaminérgicas del mesencéfalo (mDA)
US8772233B2 (en) Method for promoting regeneration of pancreatic beta-cells by administering neurturin
US20050186182A1 (en) Methods of using G-CSF mobilized C-Kit+ cells in the production of embryoid body-like cell clusters for tissue repair and in the treatment of cardiac myopathy
JP7041515B2 (ja) 骨、骨髄、及び軟骨の誘導を提供する因子及び細胞
CN1452492A (zh) 神经保护肽
CN101802174A (zh) 细胞增殖方法以及用于组织修复及再生的药物
CN1141058A (zh) 中枢神经系统干细胞的原位修饰和处理
JP2007143554A (ja) 細胞移植方法及び試薬
US10870830B2 (en) Method for culturing differentiation-promoting and -sustaining spheroid form of tonsil-derived stem cells
CN104884611A (zh) Nprcp、pfdnc和它们的应用
US6749850B1 (en) Methods, compositions and kits for promoting recovery from damage to the central nervous system
CN1307632A (zh) 室管膜神经干细胞及其分离方法
JP6791854B2 (ja) 組織適用におけるｌｇｒ４、ｌｇｒ５およびｌｇｒ６発現上皮幹細胞を用いた最小限分極機能性細胞微細凝集塊単位の開発および使用のための方法
AU741350B2 (en) Treatment of mammalian myocardium with morphogen locally, or with morphogenically-treated myogenic precursor cells
CN1871340A (zh) 从胚胎干细胞体外生产γ－氨基丁酸能神经元及其在神经障碍治疗中的应用
US20230174943A1 (en) Cellular composition and uses thereof
JP2005118005A (ja) 肝臓集積性細胞
RU2523574C1 (ru) Способ активации регенерации миелоидной ткани старых лабораторных животных

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication